Various factors contribute to the growth of the Methicillin-resistant Staphylococcus aureus (MRSA) market, making it a dynamic and evolving landscape. The surge in MRSA infections is notably propelled by an increased prevalence of these infections globally. The rise in the number of MRSA cases can be attributed to factors such as the growing population, particularly in emerging markets, where healthcare infrastructure is witnessing a noteworthy upward trend.
One significant driver is the steady growth of the elderly and immune-compromised population. As the aging demographic expands and more individuals become susceptible to infections, the demand for MRSA drugs intensifies. Additionally, factors like easy accessibility to treatment, the availability of medications, and strategically positioned stocking points contribute to addressing MRSA infections promptly, leading to a higher treatment-seeking population.
Raising awareness about MRSA infections is a pivotal aspect of combating the spread of antibiotic-resistant strains. Various initiatives and events play a crucial role in disseminating information and promoting judicious antibiotic use. For instance, World MRSA Awareness Month, observed in October, aims to educate and create awareness about MRSA. The European Antibiotic Awareness Day, celebrated on November 18, 2014, focuses on combating antibiotic resistance. Programs like World Hand Hygiene Day, National Infection Control Week, World Pneumonia Day, and Antibiotic Awareness Week contribute significantly to informing the public about preventive measures and responsible antibiotic usage.
The US Department of Health and Human Services has formulated Healthy People 2020, emphasizing the prevention and treatment of infectious diseases. These awareness programs not only educate the public but also contribute to an increased number of individuals seeking treatment, thereby fostering market growth.
The growing awareness of diseases, including MRSA infections, plays a pivotal role in driving market expansion. Heightened awareness leads to an increased utilization of drugs and medications to address and prevent infections, driving up the overall demand for MRSA drugs.
The escalating demand for MRSA drugs not only benefits the pharmaceutical industry through greater sales volume but also creates incentives for substantial investments in research and development. Pharmaceutical companies are compelled to invest in innovative solutions and drug development to meet the rising demand and effectively combat MRSA infections.
In conclusion, the MRSA market is significantly influenced by a combination of factors, including the prevalence of infections, demographic shifts, awareness programs, and increased demand for treatment. As the understanding of MRSA infections grows and initiatives to educate the public gain momentum, the market is poised for continuous expansion, driving advancements in research and development to combat antibiotic-resistant strains effectively.
Report Attribute/Metric | Details |
---|
The MRSA Drugs Market is projected to reach USD 4130.46 Million by 2030 at 4.4% CAGR during the forecast period 2022-2030. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.
The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.
Market Dynamics
MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.
MRSA Drugs Market Share, by MRSA Type, 2016 & 2023 Â
Source: MRFR Analysis
Segmentation
The MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.
North America MRSA Drugs Market Share, 2016 (%) Â
Source: MRFR Analysis
Regional Analysis
The MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.
Europe holds the second position in MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.
Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the MRSA drugs market.
Key Players
The prominent players in the MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).
Some of the key strategies followed by players operating in the MRSA drugs market were innovation, product development, and acquisition & mergers.
Market Segmentation
MRSA Drugs Market, by Drug Class
MRSA Drugs Market, by MRSA Type
MRSA Drugs Market, by Disease Indication
MRSA Drugs Market, by End User
MRSA Drugs Market, by Region
Available Additional Customizations
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)